Subscribe to Newsletter

Manufacture

Manufacture Analytical Science

From UV to MIR: the biomass monitoring spectrum

| Dörte Solle, Philipp Biechele, Christoph Busse and Thomas Scheper

Can sophisticated (spectroscopic) sensors streamline bioprocess monitoring to better meet FDA standards?

Manufacture Analytical Science

Not Spoiling the (Biopharma) Broth

| Dörte Solle, Philipp Biechele, Christoph Busse and Thomas Scheper

Can sophisticated (spectroscopic) sensors streamline bioprocess monitoring to better meet FDA standards?

Manufacture Facilities

Fumigation of the Future

| Andrew Ramage

A choice of fumigants are available for fumigating microbiological safety cabinets and high-level containment rooms. One substance that is still used in the industry is formaldehyde, but given that formaldehyde is toxic, carcinogenic and corrosive, you’d be better looking for alternatives.

Manufacture Small Molecules

The Case for Continuous

| Reiner Lemperle

“Batch is best,” according to many in the industry, but when cost reductions and greater efficiencies are a priority, continuous processing is becoming increasingly compelling.

Manufacture

Fighting Flu with Imitation Antibodies

Scientists use computationally designed imitation antibodies to fight the flu – and production costs.

Manufacture Quality & Compliance

Vendors Reloaded

Medicine packaging leaders forming the “Matrix Alliance” will bring improved container and closure systems to market.

Manufacture Advanced Medicine

Personalized Medicine × Nanotechnology

The combination of genomic profiling and high-tech targeted drug delivery is opening up a new front in the fight against cancer.

Manufacture Packaging

Lost in Translation

Translating medicine packaging information for international markets is a major challenge.

Manufacture Standards & Regulation

Problem Plants

Regulators come down hard on facilities that come up short.

Manufacture Standards & Regulation

Competition Crackdown

The UK Competition and Markets Authority (CMA) has handed out a £37.6 million fine to GSK for paying out “value transfers totaling over 50 million pounds” to competitors between 2001 and 2004 to delay the introduction of generic versions of its branded anti-depressant drug, Seroxat (paroxetine).

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register